Table 3.
Demographics of patients harboring ALK rearrangement
| Patient ID | Age/gender | Regimen number/treatment | Treatment duration, mo | Best overall response |
|---|---|---|---|---|
| 0660-6021 | 57/M | 1. Carboplatin, pemetrexed | 1.2 | UNK |
| 2. Carboplatin, paclitaxel | 2 | UNK | ||
| 3. Cisplatin, gemcitabine | 1 | UNK | ||
| 4. Ganetespib | 21 (ongoing) | PR | ||
| 0059-6005 | 79/M | 1. Bevacizumab, carboplatin, paclitaxel | 5 | SD |
| 2. Bevacizumab | 19 | SD | ||
| 3. Erlotinib | 10 | SD | ||
| 4. Carboplatin, pemetrexed | 6 | PD | ||
| 5. Ganetespib | 14.8 | PR | ||
| 0654-6006 | 67/M | 1. Bevacizumab, carboplatin, paclitaxel | 2.8 | SD |
| 2. Sunitinib | 1.4 | PD | ||
| 3. Ganetespib | 8.8 | PR | ||
| 0660-6016 | 68/M | 1. Celebrex or placebo, erlotinib | 1.8 | PD |
| 2. Pemetrexed, carboplatin | 2.8 | SD | ||
| 3. Ganetespib | 7.4 | PR | ||
| 0059-6003 | 68/M | 1. Pemetrexed, carboplatin | 3.5 | SD |
| 2. Ganetespib | 11.7 | SD | ||
| 0002-6019 | 70/M | 1. Cisplatin, vinorelbine | 2.8 | SD |
| 2. Pemetrexed | 2.5 | SD | ||
| 3. Ganetespib | 5.8 | SD | ||
| 0002-6016 | 64/F | 1. Pemetrexed, carboplatin | 0.9 | PD |
| 2. Vinorelbine | 0.9 | PD | ||
| 3. Gemcitabine | 4.1 | SD | ||
| 4. Docetaxel | 3.5 | SD | ||
| 5. AZD6244 (investigational) | 4.1 | SD | ||
| 6. Ganetespib | 3.0 | SD | ||
| 0652-6003 | 44/F | 1. Carboplatin, gemcitabine | 2.3 | PD |
| 2. Erlotinib | 2.2 | PD | ||
| 3. Bevacizumab, pemetrexed | 3.9 | PD | ||
| Pemetrexed | 17.7 | PD | ||
| Bevacizumab | 7.6 | PD | ||
| 4. Bevacizumab, erlotinib | 1.4 | PD | ||
| Erlotinib | 0.7 | PD | ||
| 5. Xytotax | 0.7 | PD | ||
| 6. Paclitaxel | 7.0 | PD | ||
| 7. Ganetespib | 1.3 | PD |
Abbreviations: F, female; M, male; UNK, unknown.